SynthesisPituitary2023
Efficacy and safety of cavernous sinus medial wall resection in pituitary adenoma surgery: a systematic review and a single-arm meta-analysis.
Synthesis in Pituitary, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Endocrine and surgical outcomes after medial cavernous sinus wall resection for functioning pituitary adenomas: a systematic review and meta-analysis.Neurosurgical review · 2026Pooled it
- Endoscopic Transsphenoidal Selective Resection of the Medial Wall of the Cavernous Sinus for the Treatment of Functional Pituitary Adenomas.Journal of neurological surgery. Part B, Skull base · 2026Article
- Endoscopic resection of knosp grade 0-2 growth hormone-secreting pituitary adenomas with routine medial cavernous sinus wall excision.Acta neurochirurgica · 2026Article
- Selective resection of the medial wall of the cavernous sinus in acromegaly: patient series.Journal of neurosurgery. Case lessons · 2026Article
- Article
- The feedback loop in pituitary surgery.Pituitary · 2025Article
- Endoscopic Transsphenoidal Sellar Surgery via One Nostril: Own Experience and Systematic Review of the Literature.Life (Basel, Switzerland) · 2025Review
- Prolactinoma Resection in a Transgender Woman on Gender-affirming Hormone Therapy.JCEM case reports · 2025Article
- High-Resolution MR Imaging of the Parasellar Ligaments.AJNR. American journal of neuroradiology · 2025Article
- Cost outcomes of pituitary adenoma resection: The use of a hybrid microscopic/endoscopic surgery.Surgical neurology international · 2025Article
- Endoscopic endonasal transcavernous approach for removal of pituitary macroadenoma with apoplexy: Technical nuances.Surgical neurology international · 2025Article
- Bibliometric analysis of the Top 1000 most-cited articles in otolaryngology over the past decade: global research trends and hotspots.Frontiers in surgery · 2025Article
- Predicting tumor progression in non-functioning pituitary macroadenomas following transnasal transsphenoidal resection: insights from a single-center retrospective cohort study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPituitary adenomas, benign tumors, can lower quality of life. Pituitary adenomas that invade the medial wall and cavernous sinus (CS) indicate tumor recurrence and partial surgical excision. Despite the cavernous sinus's complexity and risks, new research has improved the surgical procedure and made excision safer. This comprehensive review and single-arm meta-analysis evaluates endocrinological remission and resection rates in pituitary adenomas to determine the benefits and risks of MWCS resection.
methodsDatabases were systematically searched for studies documenting the resection of the medial wall of the cavernous sinus. The primary outcome was endocrinological remission in patients who underwent resection of the MWCS.
resultsEight studies were included in the final analysis. The pooled proportion of endocrinological remission (ER) was 63.3%. The excision of MWCS pooled a gross total resection (GTR) proportion of 72.9%. Finally, ICA injury attained a pooled ratio of 0.5%, indicating minimal morbidity in the procedure.
conclusionThe cavernous sinus was ruled out, proving the MWCS excision is safe. Limiting population selection to Knosp 3A or lower enhanced GTR frequencies and lowered recurrence, according to subgroup analyses. This meta-analysis shows that MWCS resection can be a beneficial treatment option for pituitary tumors, when there is no macroscopic medial wall invasion and careful patient selection is done, especially for GH- and ACTH-producing tumors that can cause life-threatening metabolic changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.